Kura Oncology, Inc. (KURA) Profit Margins
Over the twelve months to 2026-06-30, Kura Oncology, Inc. (KURA) had operating margin -411.9%, net margin -384.3%, free cash flow margin -152.1%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KURAKura Oncology, Inc.Follow KURA — free
—
Price chart with a free account
- Market cap
- 854.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Gross margin | — | 99.9% | — | |
| Operating margin | -358.5% | -449.9% | -411.9% | |
| Net margin | -322.9% | -412.9% | -384.3% | |
| FCF margin | 248.4% | -104.8% | -152.1% |
USD millions · SEC XBRL
Kura Oncology, Inc. — questions
- What is Kura Oncology, Inc.'s operating margin?
- -411.9% over the twelve months to 2026-06-30.
- What is Kura Oncology, Inc.'s net profit margin?
- -384.3% over the twelve months to 2026-06-30.
Every figure on this page comes from Kura Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.